Table 4.
Risk of ESRD and cumulative lifetime dose of Paracetamol, ASA, and substances containing neither ASA nor Paracetamol (mainly Ibuprofen) in any combination (mono- or combi) versus low use1
| Dose (tertiles) | Range (grams) | Cases | Controls | OR (95% CI) | |
| No/rare use | 546 | 2030 | 1.0 (referent) | ||
| ASA | I | < 50 | 96 | 431 | 0.96 (0.60–1.54) |
| II | 50–162 | 77 | 443 | 0.77 (0.46–1.27) | |
| III | 163+ | 114 | 432 | 1.07 (0.64–1.77) | |
| Paracetamol | I | < 17 | 61 | 297 | n.d.2 |
| II | 17–74 | 65 | 304 | 0.95 (0.63–1.42) | |
| III | 75+ | 77 | 296 | 1.11 (0.74–1.67) | |
| Other | I | < 12 | 38 | 208 | 0.66 (0.41–1.08) |
| II | 12–73 | 47 | 215 | 0.79 (0.50–1.23) | |
| III | 74+ | 63 | 209 | n.d.2 |
1 Standard reference group with exposure to less than one tablet or unit dose of any phenacetin-free analgesic compound per month across all 12-months periods in the observed lifetime. Unmatched analysis; Adjustment for family history, soldering fumes, solvents, education, and for age, sex, country. Adjustment for confounding by all other analgesic combinations.
2 dropped due to collinearity
n.d. = no data